This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $562,014 to the University of California, San Diego (UCSD) for a project titled "Opioid Actions on the Habenulo-Peduncular Circuit". The project aims to investigate the role of the medial habenula and interpeduncular nucleus in mediating the aversive qualities of opioid dependence and withdrawal, using a combination of molecular,...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under CFDA Program 93.853 "Extramural Research Programs in the Neurosciences and Neurological Disorders", provides $603,406 to Research Triangle Institute (RTI International) to develop and evaluate GPR139 antagonists as potential adjuvants to morphine for the treatment of pain. The project aims to optimize the potency, selectivity, and drug-like properties of GPR139...
This $459,613 Project Grant awarded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants (CFDA 93.242) program aims to investigate modulating endogenous opioid signaling as a potential treatment for deficits in reward processing associated with psychiatric disorders. The project will administer a drug that inhibits the degradation of endogenous enkephalins to chronically stressed mice and record neural activity in reward-related brain regions as the mice...
This Project Grant award of $2,902,673.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) is focused on establishing OPRM1 exon 7-associated variants as novel therapeutic targets to mitigate adverse effects of clinically used mu opioids without altering analgesia in pain management. The research aims to characterize antisense oligonucleotides (ASOs) and rabbit monoclonal antibodies (RABMABs) targeting mouse OPRM1 exon 7...
Nobilis Therapeutics Inc. received a $959,976 Project Grant award from the National Institute on Drug Abuse within the Department of Health and Human Services' National Institutes of Health to develop a portable hand-held xenon inhaler device for rapidly reducing opioid withdrawal symptoms. The award, made on September 30, 2021 under the Drug Abuse and Addiction Research Programs (CFDA 93.279) federal grant program, will fund preclinical proof-of-concept studies through May 29, 2023 to...
This federal Project Grant award for $340,000 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund research to better understand the role of the locus coeruleus-noradrenergic (LC-NE) system in fentanyl withdrawal-induced negative affect behaviors. The research aims to determine whether a newly identified midbrain glutamatergic input to the LC contributes to the negative affective behaviors associated with opioid withdrawal....
This $144,362 Project Grant was awarded on July 23, 2024 by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) federal grant program. The grant supports research to investigate the neural mechanisms underlying the relationship between chronic alcohol exposure and heightened pain sensitivity during alcohol withdrawal. Specifically, the research aims to determine how chronic alcohol exposure impacts the activity of neuropeptide Y...
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $267,310 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Regents of the University of Minnesota. The award will fund research to investigate the role of the neuropeptide VGF and its derived peptide TLQP-62 in facilitating synaptic plasticity in the nucleus accumbens and their contribution to opioid withdrawal behaviors. Key research activities include...
This five-year, $573,638 project grant from the National Institute on Drug Abuse, part of the Department of Health and Human Services, supports research into the neural mechanisms of individual differences in cocaine avoidance. Funded under the Drug Abuse and Addiction Research Programs (CFDA 93.279), the grant to the Medical University of South Carolina will examine cellular mechanisms by which serotonin and glutamate receptors in the rostromedial tegmental nucleus drive aversive conditioning...
This Project Grant award, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research on the neural correlates and behavioral impact of withdrawal-induced hyperalgesia (increased pain sensitivity) among people who smoke, with and without chronic pain. The $1,485,691 award to Duke University will be used to evaluate: 1) the impact of smoking withdrawal on brain fMRI response to noxious heat stimuli, and 2) the...